Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens

Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, a...

Full description

Saved in:
Bibliographic Details
Published inApplied and environmental microbiology Vol. 84; no. 12; p. e00052-18
Main Authors Li, Qian, Montalban-Lopez, Manuel, Kuipers, Oscar P.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 15.06.2018
Subjects
Online AccessGet full text
ISSN0099-2240
1098-5336
1098-5336
DOI10.1128/AEM.00052-18

Cover

Loading…
Abstract Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa , Enterobacter aerogenes ) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens. IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction.
AbstractList Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa , Enterobacter aerogenes ) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens. IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction.
Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction.Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction.
Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.
Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., , , , , ) was increased 4- to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens. Lantibiotics are antimicrobial peptides that are highly active against Gram-positive bacteria but that have relatively poor activity against most Gram-negative bacteria. Here, we modified the model lantibiotic nisin by fusing parts of it to antimicrobial peptides with known activity against Gram-negative bacteria. The appropriate selection of peptidic moieties that could be attached to (parts of) nisin could lead to a significant increase in its inhibitory activity against Gram-negative bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-fold higher levels of activity against relevant Gram-negative bacterial species were produced. This study shows the power of modified peptide engineering to alter target specificity in a desired direction.
Author Li, Qian
Kuipers, Oscar P.
Montalban-Lopez, Manuel
Author_xml – sequence: 1
  givenname: Qian
  surname: Li
  fullname: Li, Qian
  organization: Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands
– sequence: 2
  givenname: Manuel
  surname: Montalban-Lopez
  fullname: Montalban-Lopez, Manuel
  organization: Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands, Department of Microbiology, Faculty of Sciences, University of Granada, Granada, Spain
– sequence: 3
  givenname: Oscar P.
  surname: Kuipers
  fullname: Kuipers, Oscar P.
  organization: Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29625984$$D View this record in MEDLINE/PubMed
BookMark eNptkb1vFDEQxS0URC6BjhpZoqFgw9jeD7tBukQhRDoCBdTWrNe752jXDrYvUv57fCRBEFFNMb95evPeETnwwVtCXjM4YYzLD-vzLycA0PCKyWdkxUDJqhGiPSArAKUqzms4JEcpXReqhla-IIdctbxRsl4RvPQmWkzOTzRvLV377BZnYugdznRtsrt1-Y6GkV65AlWnmOxAN1iw3oXsTKI4ofMp04uIS3VlJyw3ln7DvA2T9ekleT7inOyrh3lMfnw6_372udp8vbg8W28qI2qeq152zSgGBDYClwijANZ1fWulFMbwrqkbGOQg1ahwFGiFRS5YK6USA1iU4ph8vNe92fWLHYz1OeKsb6JbMN7pgE7_u_Fuq6dwq0sQDDooAu8eBGL4ubMp68UlY-cZvQ27pDlwriQXqivo2yfoddhFX94rVCdqpUrohXrzt6M_Vh7TLwC_B0reKUU7auNyiS_sDbpZM9D7inWpWP-uWLP9n--fHD3q_hf_Ba6_p1c
CitedBy_id crossref_primary_10_1021_acs_chemrev_2c00210
crossref_primary_10_1093_femsle_fnae031
crossref_primary_10_26508_lsa_202302509
crossref_primary_10_3390_pr12081766
crossref_primary_10_1016_j_ijfoodmicro_2020_109007
crossref_primary_10_1080_17460441_2020_1699530
crossref_primary_10_1080_17460441_2024_2441351
crossref_primary_10_1016_j_jhazmat_2024_133976
crossref_primary_10_1016_j_jddst_2023_105246
crossref_primary_10_3390_foods13111606
crossref_primary_10_1021_acs_jafc_0c07816
crossref_primary_10_61186_jhehp_9_2_100
crossref_primary_10_3389_fmicb_2019_01508
crossref_primary_10_1093_femsre_fuad023
crossref_primary_10_5812_archcid_148571
crossref_primary_10_1021_acsinfecdis_0c00389
crossref_primary_10_3168_jds_2020_19350
crossref_primary_10_1016_j_molstruc_2024_139614
crossref_primary_10_3389_fbioe_2021_692466
crossref_primary_10_1007_s00213_019_05224_0
crossref_primary_10_1016_j_jiph_2024_102501
crossref_primary_10_3390_microorganisms11020501
crossref_primary_10_1016_j_chembiol_2020_07_005
crossref_primary_10_3390_ijms25052655
crossref_primary_10_1021_acssynbio_1c00161
crossref_primary_10_1021_acs_jafc_2c00232
crossref_primary_10_3389_fmicb_2025_1526250
crossref_primary_10_1007_s00203_020_02005_8
crossref_primary_10_3390_molecules27092675
crossref_primary_10_1007_s00253_019_10187_5
crossref_primary_10_3390_ani13101633
crossref_primary_10_3390_antibiotics9060330
crossref_primary_10_1016_j_lwt_2019_108915
crossref_primary_10_3390_microorganisms12061230
crossref_primary_10_1038_s42003_020_01511_1
crossref_primary_10_1016_j_ijbiomac_2025_140127
crossref_primary_10_3390_foods9091203
crossref_primary_10_1016_j_bcab_2022_102317
crossref_primary_10_1128_MMBR_00007_19
crossref_primary_10_3389_fmars_2021_659519
crossref_primary_10_1016_j_ijantimicag_2019_03_009
crossref_primary_10_1111_wrr_12909
crossref_primary_10_1038_s41598_023_49466_7
crossref_primary_10_1016_j_micpath_2020_104320
crossref_primary_10_1016_j_copbio_2020_12_022
crossref_primary_10_1186_s12917_024_03985_1
crossref_primary_10_3168_jds_2019_17498
crossref_primary_10_1186_s12864_021_08005_2
crossref_primary_10_1016_j_foodcont_2021_108778
crossref_primary_10_1080_10826068_2023_2209892
crossref_primary_10_1002_adma_202304991
crossref_primary_10_3389_fmicb_2018_03006
crossref_primary_10_3390_microorganisms12071259
crossref_primary_10_1016_j_bmc_2019_06_031
crossref_primary_10_1042_BST20200425
crossref_primary_10_1016_j_lwt_2021_112777
crossref_primary_10_3389_fmicb_2024_1406672
crossref_primary_10_1021_acssynbio_4c00650
crossref_primary_10_3389_fmicb_2020_592220
crossref_primary_10_1111_mmi_14183
crossref_primary_10_1128_AAC_02050_19
crossref_primary_10_3390_foods12193520
crossref_primary_10_1039_D3FO05619H
crossref_primary_10_1007_s10570_024_06039_9
crossref_primary_10_3390_antibiotics13050415
crossref_primary_10_3390_microorganisms11020427
crossref_primary_10_1128_AEM_00391_21
crossref_primary_10_1016_j_ijbiomac_2024_135389
crossref_primary_10_1016_j_afres_2025_100693
crossref_primary_10_1159_000543664
crossref_primary_10_1016_j_procbio_2022_09_030
crossref_primary_10_3390_ijms23094685
crossref_primary_10_1186_s12866_024_03400_7
crossref_primary_10_1016_j_ijbiomac_2025_141961
crossref_primary_10_1186_s12934_023_02041_1
crossref_primary_10_1111_aji_13096
crossref_primary_10_1021_jacs_1c09370
crossref_primary_10_1093_femsre_fuaa021
crossref_primary_10_1128_AEM_00186_21
crossref_primary_10_1021_acssynbio_1c00080
crossref_primary_10_3389_fmicb_2020_598789
crossref_primary_10_1007_s12033_022_00584_z
crossref_primary_10_1002_ps_5859
crossref_primary_10_1016_j_bios_2022_114809
crossref_primary_10_1128_JB_00639_19
crossref_primary_10_1134_S0006297920110048
crossref_primary_10_1016_j_colsurfb_2021_111965
crossref_primary_10_1139_cjm_2019_0292
crossref_primary_10_1128_mBio_02825_20
crossref_primary_10_5851_kosfa_2022_e48
crossref_primary_10_3390_antibiotics9030128
crossref_primary_10_1021_acsinfecdis_0c00001
crossref_primary_10_3390_ijms22073480
crossref_primary_10_1007_s00018_021_03759_0
crossref_primary_10_3390_ph16081058
crossref_primary_10_3390_pharmaceutics14010076
crossref_primary_10_1016_j_resmic_2021_103836
crossref_primary_10_1038_s41579_024_01045_x
crossref_primary_10_3389_fmicb_2020_561060
crossref_primary_10_1016_j_foodres_2022_112363
crossref_primary_10_3390_pharmaceutics13010086
Cites_doi 10.1128/CMR.14.4.933-951.2001
10.1016/j.bbrc.2004.08.144
10.1016/j.peptides.2004.03.016
10.1128/AAC.00883-09
10.1126/science.1121422
10.1021/sb3001084
10.1007/s10989-011-9284-6
10.1128/aem.62.10.3662-3667.1996
10.1074/jbc.M109.026690
10.1128/JB.154.1.1-9.1983
10.1126/science.1129818
10.1128/AEM.02350-06
10.1517/17425255.2011.573478
10.3390/jdb4010007
10.1016/j.peptides.2008.07.016
10.3389/fmicb.2015.00011
10.1016/S0021-9258(18)42830-X
10.1016/j.febslet.2008.06.015
10.1128/AEM.01104-07
10.1016/j.ijantimicag.2011.07.012
10.1016/j.dci.2010.12.011
10.1016/j.cbpb.2009.10.003
10.3389/fmicb.2018.00160
10.1007/s00018-007-7171-2
10.1038/nprot.2006.4
10.1038/nprot.2007.521
10.1016/S0168-1605(99)00139-7
10.1128/aem.57.12.3613-3615.1991
10.1002/psc.2551
10.1074/jbc.270.45.27299
10.1074/jbc.M006770200
10.1038/nm1145
10.1021/bi700106z
10.1038/nrd2004
10.1021/bi050081h
10.1016/S0168-1605(00)00307-X
10.1016/S0167-7799(97)01029-9
10.1074/jbc.M312789200
ContentType Journal Article
Copyright Copyright © 2018 American Society for Microbiology.
Copyright American Society for Microbiology Jun 15, 2018
Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology
Copyright_xml – notice: Copyright © 2018 American Society for Microbiology.
– notice: Copyright American Society for Microbiology Jun 15, 2018
– notice: Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology
DBID AAYXX
CITATION
NPM
7QL
7QO
7SN
7SS
7ST
7T7
7TM
7U9
8FD
C1K
FR3
H94
M7N
P64
RC3
SOI
7X8
5PM
DOI 10.1128/AEM.00052-18
DatabaseName CrossRef
PubMed
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Virology and AIDS Abstracts
Technology Research Database
Nucleic Acids Abstracts
Ecology Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Entomology Abstracts
Genetics Abstracts
Biotechnology Research Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Environment Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
Virology and AIDS Abstracts

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Economics
Engineering
Biology
DocumentTitleAlternate Engineering Nisin against Gram-Negative Bacteria
EISSN 1098-5336
ExternalDocumentID PMC5981070
29625984
10_1128_AEM_00052_18
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: 201306770012
GroupedDBID ---
-~X
0R~
23M
2WC
39C
4.4
53G
5GY
5RE
5VS
6J9
85S
AAGFI
AAYXX
AAZTW
ABOGM
ABPPZ
ACBTR
ACGFO
ACIWK
ACNCT
ACPRK
ADBBV
ADUKH
AENEX
AFRAH
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BKOMP
BTFSW
CITATION
CS3
D0L
DIK
E.-
E3Z
EBS
EJD
F5P
GX1
H13
HYE
HZ~
K-O
KQ8
L7B
O9-
P2P
PQQKQ
RHI
RNS
RPM
RSF
RXW
TAE
TN5
TR2
TWZ
UHB
W8F
WH7
WOQ
X6Y
~02
~KM
NPM
OK1
RHF
UCJ
Z5M
7QL
7QO
7SN
7SS
7ST
7T7
7TM
7U9
8FD
C1K
FR3
H94
M7N
P64
RC3
SOI
7X8
5PM
TAF
ID FETCH-LOGICAL-c342t-b875f3da01f028a0f30177b6e883cc275450d8d89f9af3ae3ea23168893d0ea83
ISSN 0099-2240
1098-5336
IngestDate Thu Aug 21 13:20:43 EDT 2025
Thu Jul 10 20:03:26 EDT 2025
Mon Jun 30 08:46:22 EDT 2025
Wed Feb 19 02:36:24 EST 2025
Tue Jul 01 02:20:12 EDT 2025
Thu Apr 24 23:07:39 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Gram-negative pathogens
lantibiotic
outer membrane
nisin
antimicrobial activity
antimicrobial peptide
Language English
License Copyright © 2018 American Society for Microbiology.
All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c342t-b875f3da01f028a0f30177b6e883cc275450d8d89f9af3ae3ea23168893d0ea83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Citation Li Q, Montalban-Lopez M, Kuipers OP. 2018. Increasing the antimicrobial activity of nisin-based lantibiotics against Gram-negative pathogens. Appl Environ Microbiol 84:e00052-18. https://doi.org/10.1128/AEM.00052-18.
OpenAccessLink https://aem.asm.org/content/aem/84/12/e00052-18.full.pdf
PMID 29625984
PQID 2073499240
PQPubID 42251
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5981070
proquest_miscellaneous_2022982397
proquest_journals_2073499240
pubmed_primary_29625984
crossref_citationtrail_10_1128_AEM_00052_18
crossref_primary_10_1128_AEM_00052_18
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-06-15
PublicationDateYYYYMMDD 2018-06-15
PublicationDate_xml – month: 06
  year: 2018
  text: 2018-06-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Applied and environmental microbiology
PublicationTitleAlternate Appl Environ Microbiol
PublicationYear 2018
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_3_17_2
e_1_3_3_16_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_13_2
e_1_3_3_12_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_32_2
e_1_3_3_33_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_10_2
e_1_3_3_31_2
e_1_3_3_40_2
Sambrook J (e_1_3_3_36_2) 2001
e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_28_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_26_2
e_1_3_3_25_2
Holo H (e_1_3_3_37_2) 1995; 47
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
e_1_3_3_3_2
e_1_3_3_21_2
References_xml – ident: e_1_3_3_31_2
  doi: 10.1128/CMR.14.4.933-951.2001
– ident: e_1_3_3_21_2
  doi: 10.1016/j.bbrc.2004.08.144
– volume-title: Molecular cloning: a laboratory manual
  year: 2001
  ident: e_1_3_3_36_2
– ident: e_1_3_3_19_2
  doi: 10.1016/j.peptides.2004.03.016
– ident: e_1_3_3_40_2
  doi: 10.1128/AAC.00883-09
– ident: e_1_3_3_6_2
  doi: 10.1126/science.1121422
– ident: e_1_3_3_35_2
  doi: 10.1021/sb3001084
– ident: e_1_3_3_25_2
  doi: 10.1007/s10989-011-9284-6
– ident: e_1_3_3_8_2
  doi: 10.1128/aem.62.10.3662-3667.1996
– volume: 47
  start-page: 195
  year: 1995
  ident: e_1_3_3_37_2
  article-title: Transformation of Lactococcus by electroporation
  publication-title: Methods Mol Biol
– ident: e_1_3_3_29_2
  doi: 10.1074/jbc.M109.026690
– ident: e_1_3_3_34_2
  doi: 10.1128/JB.154.1.1-9.1983
– ident: e_1_3_3_13_2
  doi: 10.1126/science.1129818
– ident: e_1_3_3_10_2
  doi: 10.1128/AEM.02350-06
– ident: e_1_3_3_11_2
  doi: 10.1517/17425255.2011.573478
– ident: e_1_3_3_17_2
  doi: 10.3390/jdb4010007
– ident: e_1_3_3_18_2
  doi: 10.1016/j.peptides.2008.07.016
– ident: e_1_3_3_32_2
  doi: 10.3389/fmicb.2015.00011
– ident: e_1_3_3_20_2
  doi: 10.1016/S0021-9258(18)42830-X
– ident: e_1_3_3_26_2
  doi: 10.1016/j.febslet.2008.06.015
– ident: e_1_3_3_27_2
  doi: 10.1128/AEM.01104-07
– ident: e_1_3_3_23_2
  doi: 10.1016/j.ijantimicag.2011.07.012
– ident: e_1_3_3_22_2
  doi: 10.1016/j.dci.2010.12.011
– ident: e_1_3_3_24_2
  doi: 10.1016/j.cbpb.2009.10.003
– ident: e_1_3_3_28_2
  doi: 10.3389/fmicb.2018.00160
– ident: e_1_3_3_3_2
  doi: 10.1007/s00018-007-7171-2
– ident: e_1_3_3_38_2
  doi: 10.1038/nprot.2006.4
– ident: e_1_3_3_41_2
  doi: 10.1038/nprot.2007.521
– ident: e_1_3_3_15_2
  doi: 10.1016/S0168-1605(99)00139-7
– ident: e_1_3_3_16_2
  doi: 10.1128/aem.57.12.3613-3615.1991
– ident: e_1_3_3_39_2
  doi: 10.1002/psc.2551
– ident: e_1_3_3_7_2
  doi: 10.1074/jbc.270.45.27299
– ident: e_1_3_3_12_2
  doi: 10.1074/jbc.M006770200
– ident: e_1_3_3_30_2
  doi: 10.1038/nm1145
– ident: e_1_3_3_9_2
  doi: 10.1021/bi700106z
– ident: e_1_3_3_2_2
  doi: 10.1038/nrd2004
– ident: e_1_3_3_4_2
  doi: 10.1021/bi050081h
– ident: e_1_3_3_14_2
  doi: 10.1016/S0168-1605(00)00307-X
– ident: e_1_3_3_33_2
  doi: 10.1016/S0167-7799(97)01029-9
– ident: e_1_3_3_5_2
  doi: 10.1074/jbc.M312789200
SSID ssj0004068
Score 2.5628724
Snippet Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues....
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e00052-18
SubjectTerms Aerogenes
Antibiotics
Antiinfectives and antibacterials
Antimicrobial activity
Antimicrobial agents
Bacteria
Biosynthesis
E coli
Efflux
Genetics and Molecular Biology
Gram-negative bacteria
Gram-positive bacteria
Klebsiella
Lantibiotics
Membranes
Microorganisms
Nisin
Pathogens
Peptides
Pseudomonas aeruginosa
Reengineering
Tails
Title Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens
URI https://www.ncbi.nlm.nih.gov/pubmed/29625984
https://www.proquest.com/docview/2073499240
https://www.proquest.com/docview/2022982397
https://pubmed.ncbi.nlm.nih.gov/PMC5981070
Volume 84
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZgCDEeEBQYgYGMBE-VS-JkjfNY0GBiP9ikTdpb5Dj2iMSSqk0f4K_nLk5SZxRp8BJViV1HufP5O_vuO0LeKRUqQNkhk7GZsij3NZPaREzmQudJLkxummiLk-nBRfT1cu9yfYLfZJfU2UT92phX8j9ShXsgV8yS_QfJ9n8KN-A3yBeuIGG43krGMLkxprzLeJqVdXFdNMxK-OFVWxgC9wQKaMQ-woqVj4_gWxZZUVl-5itZAEAcf1nIa3airywN-CnAwgpGXbrQtcOruNPupMdh9kmxZnPqA3yaKIEzR_nAekDjTJbsqJrbfetjWa50H-JxuCrmbcW2b0slF-PTibsnEQiMnbJZmZ2dTRKGYMGuMta0InMpgMupa3ttebhOx_hmm84xT2G2fzxpziVZa68H1Nk3lrQ-0LBxcbhIoXfa9E4DcZfc4-BTYLmLwzOHWt6fio6yFF-9y5Lg4oM79hC__OGU3IytdcDK-WPyqPUy6MyqzBNyR5cjct_WHf05Ig-6dPTliDx0GCmfErlWKQoqRQcqRTuVopWhjkpRV6Voq1J0oFK0V6ln5OLz_vmnA9ZW4WAqjHjNMvBoTZhLPzCARaVvYEmI42yqhQiV4jFAcD8XuUhMIk0odaglx2poAIRh5ksRPidbZVXqF4RG2Z7IOPrIQmLxMxFEKoMOOo54rALjkXH3bVPVUtRjpZQf6SY5euR933puqVn-0m63E1PaTt5lymFpA2cf5OyRt_1jMK14XiZLXa2wDeeJ4IDYPbJjpdoPxBPcOBCRR-KBvPsGSNs-fFIW3xv6dugWwEL78pav_4psr6fYLtmqFyv9GoBwnb1pFPg3FuC1RQ
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increasing+the+Antimicrobial+Activity+of+Nisin-Based+Lantibiotics+against+Gram-Negative+Pathogens&rft.jtitle=Applied+and+environmental+microbiology&rft.au=Li%2C+Qian&rft.au=Montalban-Lopez%2C+Manuel&rft.au=Kuipers%2C+Oscar+P.&rft.date=2018-06-15&rft.issn=0099-2240&rft.eissn=1098-5336&rft.volume=84&rft.issue=12&rft_id=info:doi/10.1128%2FAEM.00052-18&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_AEM_00052_18
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0099-2240&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0099-2240&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0099-2240&client=summon